Corbus Pharmaceuticals Holdings (STU:3371) Total Current Liabilities: €15.69 Mil (As of Mar. 2026)


STU:3371 Corbus Pharmaceuticals Holdings Inc STU:3371
31 GF Score
Price €8.36
! 1 Warning Sign
View Full Analysis

What is Corbus Pharmaceuticals Holdings Total Current Liabilities?

Corbus Pharmaceuticals Holdings STU:3371 +1.40% 31 Total Current Liabilities is €15.69 Mil as of Mar. 2026. GuruFocus rates STU:3371 with a GF Score™ of 31/100. The stock has 1 warning sign investors should review.

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Corbus Pharmaceuticals Holdings's total current liabilities for the quarter that ended in Mar. 2026 was €15.69

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Corbus Pharmaceuticals Holdings Total Current Liabilities Related Terms

Corbus Pharmaceuticals Holdings Total Current Liabilities Historical Data

* Premium members only.

The historical data trend for Corbus Pharmaceuticals Holdings's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Corbus Pharmaceuticals Holdings Total Current Liabilities Chart

Corbus Pharmaceuticals Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 15.05 11.93 29.25 11.29 17.67

Corbus Pharmaceuticals Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.75 11.56 14.54 17.67 15.69
STU:3371
31GF Score
Corbus Pharmaceuticals Holdings Inc STU:3371
Total Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Corbus Pharmaceuticals Holdings Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Corbus Pharmaceuticals Holdings's Total Current Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=13.835+1.395
+Other Current Liabilities+Current Deferred Liabilities
=2.441+0
=17.67

Corbus Pharmaceuticals Holdings's Total Current Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=13.581+1.042
+Other Current Liabilities+Current Deferred Liabilities
=1.066+0
=15.69

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

What does a Total Current Liabilities of €15.69 Mil mean?
Corbus Pharmaceuticals Holdings (STU:3371) has a Total Current Liabilities of €15.69 Mil as of Mar. 2026. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Corbus Pharmaceuticals Holdings and its competitors.
Is Corbus Pharmaceuticals Holdings' Total Current Liabilities too high?
Corbus Pharmaceuticals Holdings' current Total Current Liabilities is €15.69 Mil. Overall, Corbus Pharmaceuticals Holdings has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Corbus Pharmaceuticals Holdings' Total Current Liabilities compare to PRQR and NRXP?
Corbus Pharmaceuticals Holdings' Total Current Liabilities of €15.69 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Liabilities for a Biotechnology company?
A good Total Current Liabilities depends on the Biotechnology industry context. However, Total Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Liabilities mean?
A high Total Current Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Corbus Pharmaceuticals Holdings and its competitors. Corbus Pharmaceuticals Holdings's current Total Current Liabilities is €15.69 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corbus Pharmaceuticals Holdings stock overvalued right now?
Corbus Pharmaceuticals Holdings (STU:3371) has a current Total Current Liabilities of €15.69 Mil. The current Total Current Liabilities is €15.69 Mil. Corbus Pharmaceuticals Holdings' overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Liabilities calculated?
Total Current Liabilities is calculated from a company's financial statements. For Corbus Pharmaceuticals Holdings (STU:3371), the current Total Current Liabilities is €15.69 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Corbus Pharmaceuticals Holdings Business Description

Other Exchanges CRBP:USA0SZI:UK
Address 500 River Ridge Drive, Norwood, MA, USA, 02062
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
31GF Score

Get the complete analysis for STU:3371

Total Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€8.36
Price